Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study

Απλή σελίδα τεκμηρίου
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorGennatas, K.en
dc.contributor.authorBeer, M.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorKlouvas, G.en
dc.contributor.authorKarpathios, S.en
dc.contributor.authorLinardou, H.en
dc.contributor.authorKonstantaras, C.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:31:39Z
dc.date.available2015-11-24T19:31:39Z
dc.identifier.issn0959-8049-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23301
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/*therapeutic useen
dc.subjectCarcinoma/*drug therapyen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectEpirubicin/administration & dosageen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectOvarian Neoplasms/*drug therapyen
dc.subjectPrognosisen
dc.subjectProspective Studiesen
dc.subjectRemission Inductionen
dc.subjectSurvival Analysisen
dc.subjectSurvival Rateen
dc.titleCarboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group studyen
heal.abstractWe compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CB-EC) in advanced ovarian cancer patients. The treatment was scheduled to be administered every 3 weeks for six courses. Following initial laparotomy and cytoreductive surgery, 130 previously untreated patients entered the study. 73 patients were treated with carboplatin alone while 57 received the combination chemotherapy. In the majority of the patients, the regimens had to be given every 4 weeks due to myelosuppression. Nausea, vomiting and alopecia were more severe in the CB-EC arm. Overall, clinical complete response was observed in 73 (56%) and partial response in 20 (15%) patients. The median time to progression was 16.89 months and median survival was 29.54 months. No significant differences in response rate, time to progression, disease-free survival and overall survival were observed between the two treatment arms. The prognostic role of residual disease after initial surgery, complete remission at second-look laparotomy, tumour stage and performance status was confirmed.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8814685-
heal.journalNameEur J Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1996-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ